Tissue plasminogen activator modulates the cellular and behavioral response to cocaine

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 6, 2009, Pages 1983-1988

  Maiya, Rajani ^a   Zhou, Yan ^a   Norris, Erin H ^a   Kreek, Mary Jeanne ^a   Strickland, Sidney ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Behavioral sensitization; Conditioned place preference; Corticotropin releasing factor; Neuronal signaling; Plasminogen activator inhibitor

Indexed keywords

COCAINE; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; PREPRODYNORPHIN; TISSUE PLASMINOGEN ACTIVATOR;

AMYGDALOID NUCLEUS; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; ENZYME LINKED IMMUNOSORBENT ASSAY; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LOCOMOTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TRANQUILIZING ACTIVITY; ZYMOGRAPHY;

AMYGDALA; ANIMALS; BEHAVIOR, ANIMAL; COCAINE; MICE; MICE, KNOCKOUT; MOTOR ACTIVITY; PHOSPHORYLATION; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; TISSUE PLASMINOGEN ACTIVATOR;

MUS;

EID: 60549105995     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0812491106     Document Type: Article

References (37)

1. Nestler EJ (2004) Historical review: molecular and cellular mechanisms of opiate and cocaine addiction. Trends Pharmacol Sci 25(4):210-218.
2. Kreek MJ, LaForge KS, Butelman E (2002) Pharmacotherapy of addictions. Nat Rev Drug Discov 1(9):710-726.
3. Koob G, Kreek MJ (2007) Stress, dysregulation of drug reward pathways, and the transition to drug dependence. Am J Psychiatry 164(8):1149-1159.
4. Shippenberg TS, Zapata A, Chefer VI (2007) Dynorphin and the pathophysiology of drug addiction. Pharmacol Ther 116(2):306-321.
5. Spangler R, Unterwald EM, Kreek MJ (1993) 'Binge' cocaine administration induces a sustained increase of prodynorphin mRNA in rat caudate-putamen. Brain Res Mol Brain Res 19(4):323-327.
6. Samson AL, Medcalf RL (2006) Tissue-type plasminogen activator: a multifaceted modulator of neurotransmission and synaptic plasticity. Neuron 50(5):673-678.
7. Nicole O, et al. (2001) The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med 7(1):59-64.
8. Norris EH, Strickland S (2007) Modulation of NR2B-regulated contextual fear in the hippocampus by the tissue plasminogen activator system. Proc Natl Acad Sci USA 104(33):13473-13478.
9. Pawlak R, et al. (2003) Tissue plasminogen activator in the amygdala is critical for stress-induced anxiety-like behavior. Nat Neurosci 6(2):168-174.
10. Matys T, et al. (2004) Tissue plasminogen activator promotes the effects of corticotropin-releasing factor on the amygdala and anxiety-like behavior. Proc Natl Acad Sci USA 101(46):16345-16350.
11. Kreek MJ, Koob GF (1998) Drug dependence: stress and dysregulation of brain reward pathways. Drug Alcohol Depend 51(1-2):23-47.
12. Nagai T, et al. (2004) The tissue plasminogen activator-plasmin system participates in the rewarding effect of morphine by regulating dopamine release. Proc Natl Acad Sci USA 101(10):3650-3655.
13. Bahi A, Dreyer JL (2008) Overexpression of plasminogen activators in the nucleus accumbens enhances cocaine-, amphetamine- and morphine-induced reward and behavioral sensitization. Genes Brain Behav 7(2):244-256.
14. Nagai T, et al. (2006) The rewards of nicotine: regulation by tissue plasminogen activator-plasmin system through protease activated receptor-1. J Neurosci 26(47):12374-12383.
15. Nagai T, et al. (2005) The role of tissue plasminogen activator in methamphetamine-related reward and sensitization. J Neurochem 92(3): 660-667.
16. Hashimoto T, Kajii Y, Nishikawa T (1998) Psychotomimetic-induction of tissue plasminogen activator mRNA in corticostriatal neurons in rat brain. Eur J Neurosci 10(11):3387-3399.
17. Ripley TL, et al. (1999) Increased sensitivity to cocaine, and over-responding during cocaine self-administration in tPA knockout mice. Brain Res 826(1):117-127.
18. Maisonneuve IM, Kreek MJ (1994) Acute tolerance to the dopamine response induced by a binge pattern of cocaine administration in male rats: an in vivo microdialysis study. J Pharmacol Exp Ther 268(2):916-921.
19. Unterwald EM, et al. (1994) Time course of the development of behavioral sensitization and dopamine receptor up-regulation during binge cocaine administration. J Pharmacol Exp Ther 270(3):1387-1396.
20. Zhou Y, et al. (1996) Corticotropin-releasing factor and type 1 corticotropin-releasing factor receptor messenger RNAs in rat brain and pituitary during "binge"-pattern cocaine administration and chronic withdrawal. J Pharmacol Exp Ther 279(1):351-358.
21. Sarnyai Z, Shaham Y, Heinrichs SC (2001) The role of corticotropin- releasing factor in drug addiction. Pharmacol Rev 53(2):209-243.
22. Spanagel R, Herz A, Shippenberg TS (1992) Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc Natl Acad Sci USA 89(6):2046-2050.
23. Knoll AT, et al. (2007) Anxiolytic-like effects of kappa-opioid receptor antagonists in models of unlearned and learned fear in rats. J Pharmacol Exp Ther 323(3):838-845.
24. Richter RM, et al. (1995) Sensitization of cocaine-stimulated increase in extracellular levels of corticotropin-releasing factor from the rat amygdala after repeated administration as determined by intracranial microdialysis. Neurosci Lett 187(3):169-172.
25. Lu L, et al. (2006) Role of ERK in cocaine addiction. Trends Neurosci 29(12):695-703.
26. Erb S, Brown ZJ (2006) A role for corticotropin-releasing factor in the long-term expression of behavioral sensitization to cocaine. Behav Brain Res 172(2):360-364.
27. Svenningsson P, Nairn AC, Greengard P (2005) DARPP-32 mediates the actions of multiple drugs of abuse. AAPS J 7(2):E353-E360.
28. Valjent E, et al. (2005) Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum. Proc Natl Acad Sci USA 102(2):491-496.
29. Carlezon WA, Jr, et al. (1998) Regulation of cocaine reward by CREB. Science 282(5397):2272-2275.
30. Valjent E, et al. (2006) Inhibition of ERK pathway or protein synthesis during reexposure to drugs of abuse erases previously learned place preference. Proc Natl Acad Sci USA 103(8):2932-2937.
31. Valjent E, et al. (2006) Plasticity-associated gene Krox24/Zif268 is required for long-lasting behavioral effects of cocaine. J Neurosci 26(18):4956-4960.
32. Zhang Y, et al. (2006) Cocaine self-administration in mice is inversely related to phosphorylation at Thr34 (protein kinase A site) and Ser130 (kinase CK1 site) of DARPP-32. J Neurosci 26(10):2645-2651.
33. Szumlinski KK, et al. (2004) Homer proteins regulate sensitivity to cocaine. Neuron 43(3):401-413.
34. Zhang Y, et al. (2004) Effect of the endogenous kappa opioid agonist dynorphin A(1-17) on cocaine-evoked increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice. Psychopharmacology (Berl) 172(4):422-429.
35. Valjent E, et al. (2004) Addictive and non-addictive drugs induce distinct and specific patterns of ERK activation in mouse brain. Eur J Neurosci 19(7):1826-1836.
36. Huang YY, et al. (1996) Mice lacking the gene encoding tissue-type plasminogen activator show a selective interference with late-phase long-term potentiation in both Schaffer collateral and mossy fiber pathways. Proc Natl Acad Sci USA 93(16):8699-8704.
37. Centonze D, et al. (2002) Tissue plasminogen activator is required for corticostriatal long-term potentiation. Eur J Neurosci 16(4):713-721.